TA
VRTX icon

TFB Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

TFB Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,039
Closed -$463K – 357
2025
Q2 		$463K Buy
1,039
+16
+2% +$7.37K 0.12% 194
2025
Q1 		$496K Buy
1,023
+19
+2% +$8.85K 0.14% 170
2024
Q4 		$404K Sell
1,004
-995
-50% -$461K 0.12% 199
2024
Q3 		$930K Sell
1,999
-539
-21% -$259K 0.28% 82
2024
Q2 		$1.19M Buy
2,538
+290
+13% +$126K 0.39% 58
2024
Q1 		$904K Buy
2,248
+928
+70% +$392K 0.33% 71
2023
Q4 		$537K Sell
1,320
-1,033
-44% -$382K 0.28% 84
2023
Q3 		$818K Sell
2,353
-34
-1% -$11.9K 0.99% 29
2023
Q2 		$840K Buy
2,387
+233
+11% +$78.5K 0.37% 69
2023
Q1 		$679K Buy
2,154
+541
+34% +$162K 0.52% 40
2022
Q4 		$466K Buy
+1,613
New +$492K 0.39% 52

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TFB Advisors's VRTX Position: Q3 2025 in Review

TFB Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,039 shares — an estimated $463K sold.

TFB Advisors first reported a position in VRTX in Q4 2022 and held it in 11 quarters. The position peaked at $1.19M in Q2 2024. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • TFB Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • TFB Advisors sold 1,039 Vertex Pharmaceuticals shares in Q3 2025, an estimated $463K.
  • TFB Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 11 quarters.
  • TFB Advisors's Vertex Pharmaceuticals position peaked at $1.19M in Q2 2024.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on TFB Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.